Drug Target Review rounds up the latest announcements regarding funding for research into COVID-19 treatments and vaccines.
List view / Grid view
Regs & Legs
Filter the results
The UK government has invested £20 million into the COVID-19 Genomics UK Consortium, which will use whole genome sequencing to inform infection control measures and therapeutic developments.
Drug Target Review has created a COVID-19 research hub with forum space for discussions and a place to share your research - plus all of our articles and news.
This issue includes a spotlight on how genomic assays could revolutionise healthcare, a discussion on how lab automation can improve drug discovery and an analysis of whether antibodies can provide an effective coronavirus treatment. Other article topics in this issue include immuno-oncology and artificial intelligence.
The National Drug Discovery Centre (NDDC) has opened in Australia, with support from the government to subsidise the screening of medicinal compounds.
Last year, the European Patent Office (EPO) saw the number of patents filed in the pharmaceutical and biotechnology sectors rise for the third year in a row.
The ABPI has outlined how the new immigration system in the UK will affect life science workers and businesses, emphasising the need for regular reviews to remain competitive.
New research has revealed that despite a rising number of women in STEM publishing papers, there is a large gender difference due to females leaving academia.
Arguments filed in opposition to a patent for foundation CRISPR-Cas9 intellectual property have been broadly rejected by the European Patents Office.
Boris Johnson, the Prime Minister of the UK, has announced a new Global Talent visa for researchers and scientists which will fast track those in certain fields.
The two organisations have entered into a two-year alliance to improve scientific exchange in the drug discovery industry.
Researchers have revealed that small- and medium-sized companies will by key in the growth of the life sciences sector in Scotland.
This issue includes a discussion on the future of high-throughput screening through collaboration, an analysis of mass spectrometry as a structural biology tool and an exploration of the challenges of hit-to-lead when researching tropical diseases. Also in the issue are articles on immuno-oncology and assays.